Rayvio_News_Filter
$BIIB 🏥
Biogen Inc. announced new Phase 2 CELIA data showing diranersen slowed clinical decline by 38% on CDR-SB at two years (Week 96) with the 60 mg twice-yearly regimen, corresponding to a 1.09-point treatment difference, in early Alzheimer's disease.
Selected from hundreds of headlines
2
